November 2026 · Biotech & pharma · North America
Emvena Therapeutics is developing medicines designed to be delivered directly to the placenta to address serious maternal and fetal conditions such as preeclampsia.
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-11-07 | — | — | Penn-BioNTech Fund | pulse2.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-11-10.
Kardi Ai is a non-invasive, reusable single-lead ECG medical device for adults that records and analyses the heart's electrical activity, for home or clinical use, detecting…
Switchpoint Bio combines blood-based epigenomics (DNA methylation) and AI to produce decision-grade evidence for drug development: biomarker discovery, patient stratification and…
Cell-selective mRNA therapeutics: seRNA constructs are delivered inactive and switch on only when they detect a disease-specific RNA inside the target cell, found by an AI…
Lucidome Bio is developing a vaccine that triggers antibodies against methanogens in the rumen to cut methane emissions from cattle and other ruminant livestock, including…
Efferon makes CE-marked multimodal hemoadsorption devices (Efferon LPS for adults, Efferon NEO for children) that remove endotoxin and cytokines from the blood to treat sepsis…
Develops targeted protein degrader therapeutics using its SELFTAC platform, where two small molecules cross biological barriers and self-assemble into a full degrader. First…
